CY1113874T1 - TARGETED ACCESS FACTORS GOING TO PDGFR-ALPHA AND THEIR USES - Google Patents
TARGETED ACCESS FACTORS GOING TO PDGFR-ALPHA AND THEIR USESInfo
- Publication number
- CY1113874T1 CY1113874T1 CY20131100269T CY131100269T CY1113874T1 CY 1113874 T1 CY1113874 T1 CY 1113874T1 CY 20131100269 T CY20131100269 T CY 20131100269T CY 131100269 T CY131100269 T CY 131100269T CY 1113874 T1 CY1113874 T1 CY 1113874T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pdgfr
- alpha
- antibodies
- targeted access
- access factors
- Prior art date
Links
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 abstract 3
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000011230 binding agent Substances 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Στοχευμένοι παράγοντες πρόσδεσης που κατευθύνονται στο αντιγόνο PDGFR-άλφα και χρήσεις τέτοιων παραγόντων περιγράφονται εδώ. Πιο συγκεκριμένα η εφεύρεση σχετίζεται με πλήρως ανθρώπινα μονοκλωνικά αντισώματα που στοχεύονται στο αντιγόνο PDGFR-άλφα και χρήσεις αυτών των αντισωμάτων. Πτυχές της εφεύρεσης σχετίζονται επίσης με υβριδώματα ή άλλες κυτταρικές σειρές που εκφράζουν τέτοια αντισώματα. Οι περιγραφέντες στοχευμένοι παράγοντες πρόσδεσης και τα αντισώματα είναι χρήσιμα ως διαγνωστικά και για την αντιμετώπιση ασθενειών που σχετίζονται με τη δράση και/ή την υπερέκφραση του PDGFR-άλφα.Targeted binding agents targeting the PDGFR-alpha antigen and uses of such agents are described herein. More particularly the invention relates to fully human monoclonal antibodies targeting the PDGFR-alpha antigen and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and / or overexpression of PDGFR-alpha.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83564706A | 2006-08-03 | 2006-08-03 | |
| EP07873957A EP2049571B1 (en) | 2006-08-03 | 2007-08-02 | Targeted binding agents directed to pdgfr-alpha and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1113874T1 true CY1113874T1 (en) | 2016-07-27 |
Family
ID=58448979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20131100269T CY1113874T1 (en) | 2006-08-03 | 2013-04-02 | TARGETED ACCESS FACTORS GOING TO PDGFR-ALPHA AND THEIR USES |
Country Status (1)
| Country | Link |
|---|---|
| CY (1) | CY1113874T1 (en) |
-
2013
- 2013-04-02 CY CY20131100269T patent/CY1113874T1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122816T1 (en) | TARGETED BINDING AGENTS AGAINST B7-H1 | |
| CY1123028T1 (en) | FIXED AND SOLUBLE VEGF-INHIBITING ANTIBODIES | |
| CY1114271T1 (en) | CLEANINGS, HUMAN CELLULAR PUMP, AND USE OF THESE | |
| CY1119454T1 (en) | ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA | |
| AR062268A1 (en) | BINDING AGENTS DIRECTED TO PDGFR-ALFA AND ITS USES | |
| CY1119994T1 (en) | COMPOSITIONS AND METHODS FOR INCREASING MUSCLE AND MUSCLE POWER COMPETITIVE SPECIFICALLY TON GDF8 AND / OR ACTIVITY | |
| CY1120471T1 (en) | Anti-CD70 antibodies | |
| MX338754B (en) | HUMAN ANTIBODIES AGAINST TISSULAR FACTOR. | |
| CY1117031T1 (en) | CLAUDIN-18 Monoclonal Antibodies In Cancer Treatment | |
| CY1120626T1 (en) | ANTIBODIES AND OTHER MOLECULES BIND B7-H1 AND PD-1 | |
| CY1118576T1 (en) | Proteins bound to human IL-23 antigen | |
| HUE037302T2 (en) | Preparations and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotypic antibodies | |
| EP4349868A3 (en) | Humanized and chimeric monoclonal antibodies to cd47 | |
| CY1121742T1 (en) | S100A4 ANTIBODIES AND THERAPEUTIC USES THEREOF | |
| CY1118549T1 (en) | USE OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMISTRY FOR TREATMENT OF BREAST CANCER | |
| EA201070636A1 (en) | INHIBITION OF THE PROTECTOR PROTEIN, STIMULATING MACROPHAGE (RON), AND METHODS OF ITS TREATMENT | |
| CY1116886T1 (en) | C-MET ACCESSORIES | |
| CL2007003649A1 (en) | An anti-cd70 human monoclonal antibody associated molecule conjugate; composition comprising the antibody-associated molecule conjugate; method of inhibiting the growth of tumor cells expressing cd70. | |
| SMT201300046B (en) | Animal models and therapeutic molecules | |
| CY1118714T1 (en) | HIGH CONCENTRATION HUMAN CATALOGS IN THE PROTECTION-PROTECTED HUMAN RECEPTORS-2 | |
| CY1114658T1 (en) | PRIMARY ANTIGEN COMMUNICATION Binding Proteins | |
| CY1117695T1 (en) | HIGH CONCENTRATION HUMAN VASCULAR ANTIBODIES-2 | |
| GT201200318A (en) | ANTIBODIES TO GDF8 HUMAN | |
| CY1112739T1 (en) | ANTI-CD79B ANTIBODIES AND IMMUNIZATIONS AND METHODS OF USE | |
| UA106194C2 (en) | Diagnosis and treatment of cancer using anti-ereg antibody |